» Articles » PMID: 38362011

Suppression of IL-1β Promotes Beneficial Accumulation of Fibroblast-like Cells in Atherosclerotic Plaques in Clonal Hematopoiesis

Abstract

Clonal hematopoiesis (CH) is an independent risk factor for atherosclerotic cardiovascular disease. Murine models of CH suggest a central role of inflammasomes and IL-1β in accelerated atherosclerosis and plaque destabilization. Here we show using single-cell RNA sequencing in human carotid plaques that inflammasome components are enriched in macrophages, while the receptor for IL-1β is enriched in fibroblasts and smooth muscle cells (SMCs). To address the role of inflammatory crosstalk in features of plaque destabilization, we conducted SMC fate mapping in mice modeling or CH treated with IL-1β antibodies. Unexpectedly, this treatment minimally affected SMC differentiation, leading instead to a prominent expansion of fibroblast-like cells. Depletion of fibroblasts from mice treated with IL-1β antibody resulted in thinner fibrous caps. Conversely, genetic inactivation of during plaque regression promoted fibroblast accumulation and fibrous cap thickening. Our studies suggest that suppression of inflammasomes promotes plaque stabilization by recruiting fibroblast-like cells to the fibrous cap.

Citing Articles

PRDM16 controls smooth muscle cell fate in atherosclerosis.

Tan J, Cheng L, Calhoun R, Weller A, Drareni K, Fong S bioRxiv. 2025; .

PMID: 40027729 PMC: 11870537. DOI: 10.1101/2025.02.19.639186.


Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation.

Tan H, Jiang H, Wang S Ann Hematol. 2025; .

PMID: 39988580 DOI: 10.1007/s00277-025-06244-x.


Chronic inflammation and vascular cell plasticity in atherosclerosis.

Lin A, Miano J, Fisher E, Misra A Nat Cardiovasc Res. 2024; 3(12):1408-1423.

PMID: 39653823 DOI: 10.1038/s44161-024-00569-y.


Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice.

Liu W, Hardaway B, Kim E, Pauli J, Wettich J, Yalcinkaya M J Clin Invest. 2024; 135(1).

PMID: 39531316 PMC: 11684819. DOI: 10.1172/JCI182939.


Immunomodulatory Therapy for Ischemic Heart Disease.

Zhao X, Williamson T, Gong Y, Epstein J, Fan Y Circulation. 2024; 150(13):1050-1058.

PMID: 39325497 PMC: 11521113. DOI: 10.1161/CIRCULATIONAHA.124.070368.


References
1.
Liu D, Peloso G, Yu H, Butterworth A, Wang X, Mahajan A . Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017; 49(12):1758-1766. PMC: 5709146. DOI: 10.1038/ng.3977. View

2.
Gomez D, Baylis R, Durgin B, Newman A, Alencar G, Mahan S . Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat Med. 2018; 24(9):1418-1429. PMC: 6130822. DOI: 10.1038/s41591-018-0124-5. View

3.
Yu Z, Fidler T, Ruan Y, Vlasschaert C, Nakao T, Uddin M . Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk. J Clin Invest. 2023; 133(18). PMC: 10503804. DOI: 10.1172/JCI168597. View

4.
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

5.
Fidler T, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T . The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021; 592(7853):296-301. PMC: 8038646. DOI: 10.1038/s41586-021-03341-5. View